Interferon Alpha Plus 13-Cis-Retinoic Acid Modulation of BCL-2 Plus Paclitaxel for Recurrent Small Cell Lung Cancer (SCLC): An Eastern Cooperative Oncology Group Study (E6501)

BACKGROUND: Patients with recurrent small cell lung cancer (SCLC) have dismal outcomes. The failure of salvage therapy is due to the possible development of resistance mechanisms, such as the upregulation of the anti-apoptosis protein, Bcl-2. We conducted a phase II study to evaluate if modulation o...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Chemother Pharmacol
Main Authors: Pillai, Rathi N., Aisner, Joseph, Dahlberg, Suzanne E., Rogers, John S., DiPaola, Robert S., Aisner, Seena, Ramalingam, Suresh S., Schiller, Joan H.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4296897/
https://ncbi.nlm.nih.gov/pubmed/24858462
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-014-2427-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados